Detection of mutations in EGFR in circulating lung-cancer cells by Maheswaran Shyamala, Sequist Lecia V, Nagrath Sunitha, Ulkus Lindsey, Brannigan Brian, Collura Chey V, Inserra Elizabeth, Diederichs Sven, Iafrate A John, Bell Daphne W, Digumarthy Subba, Muzikansky Alona, Irimia Daniel, Settleman Jeffrey, Tompkins Ronald G, Lynch Thomas J, Toner Mehmet, Haber Daniel A in The New England journal of medicine (2008). PubMed

Abstract

The use of tyrosine kinase inhibitors to target the epidermal growth factor receptor gene (EGFR) in patients with non-small-cell lung cancer is effective but limited by the emergence of drug-resistance mutations. Molecular characterization of circulating tumor cells may provide a strategy for noninvasive serial monitoring of tumor genotypes during treatment.

[ hide abstract ]

Discussed In Paper

Related In Paper

Variant Annotations

Sign in to see variant annotations.